To include your compound in the COVID-19 Resource Center, submit it here.

J&J reports first-in-human data for mosaic vaccine to prevent HIV infection

The Janssen Vaccines & Prevention B.V. unit of Johnson & Johnson (NYSE:JNJ) reported data from the Phase I/IIa APPROACH trial in 393 HIV-uninfected healthy volunteers showing that various mosaic-based prime-boost vaccine regimens utilizing

Read the full 333 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers